The Private Health Shift: How is the rise of private healthcare shaping the UK market?

At Ipsos, our perspective at the intersection of patient behaviour and payer decision-making is revealing how private payers (insurers, employers and self-paying consumers), are increasingly shaping access pathways beyond the public system.

However, this shift is not uniform. It presents differently across therapy areas, driven by a dynamic set of push-and-pull factors, such as public system delays and restricted reimbursement.

This creates a critical question for life science companies: to what extent should they prioritise private payers?

This paper is designed to help answer that question. Firstly, we will explore which aspects of a treatment or therapy area make it compelling enough for patients or insurers to pay by examining two contrasting case studies; obesity, with its widespread private market boom, and oncology, where the shift is more targeted towards diagnostics. Secondly, we will provide key considerations to help you determine where similar opportunities may exist within your own portfolio.